Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Barclays Reaffirms Their Buy Rating on Baxter International (BAX)

Tipranks - Tipranks - Sat Mar 14, 4:02AM CDT

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Baxter International, with a price target of $25.00.

Claim 70% Off TipRanks Premium

Miksic covers the Healthcare sector, focusing on stocks such as Alphatec Holdings, Johnson & Johnson, and Medtronic. According to TipRanks, Miksic has an average return of 3.3% and a 52.75% success rate on recommended stocks.

Currently, the analyst consensus on Baxter International is a Hold with an average price target of $19.90.

See the top stocks recommended by analysts >>

Based on Baxter International’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.97 billion and a GAAP net loss of $1.13 billion. In comparison, last year the company earned a revenue of $2.75 billion and had a GAAP net loss of $512 million

Read More on BAX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).